The Department of Pathology and Laboratory Medicine Research Program supports the common vision of The University of Vermont Medical Center and The Robert Larner, M.D. College of Medicine at The University of Vermont: teaching, research and medical service are inseparable.

Our research mission is focused on:

  • The practice of pathology and the enhancement of our understanding of pathologic mechanisms of disease. Clinical research is driven by the clinical interests of the faculty with active collaboration, where appropriate, with the basic science programs. We work within The University of Vermont Medical Center and UVM to create institutional support for productive clinical and basic research.
  • Molecular Epidemiology and Histology Research Support as core areas. The highly competitive level of science nationally and the restricted level of science funding make focused collaborative efforts necessary. We focus our basic science programs and invest departmental resources in these two core areas in order to maximize the impact of our programs and ensure continued success.
  • Creating an environment which nurtures and supports young investigators so that they may have the opportunity to develop into either independent research investigators or, in the case of more clinically oriented faculty and residents, investigative collaborators, capable of adding significantly to the scientific literature and meriting extra- and/or intramural resources.

Meet our Vice Chair for Research

Local_EWH-4356-0In her research, Professor of Pathology and Laboratory Medicine and Vice Chair for Research Yvonne Janssen-Heininger, Ph.D., focuses on chronic lung diseases, in particular the role that oxidants play in the progression of lung disease, with a goal to develop targeted redox-based therapeutics. This year, the National Heart Lung and Blood Institute honored her contributions to science by naming her an inaugural recipient of the Outstanding Investigator R35 Award. Her work, which includes over 120 published papers, has led to a patent to develop inhaled glutaredoxin as a treatment for pulmonary fibrosis, which she is continuing to explore through an SBIR grant with Celdara Medical. She has also served as a standing member on multiple NIH study sections, and has trained over 20 Ph.D. students and post-doctoral fellows. “We truly have a great team of investigators, fellows and students,” says Janssen-Heininger. “Because of our close-knit interdisciplinary group, we are able to translate findings quickly to the bedside. It is a humbling experience to try to understand and change the course of human disease. It is what drives me. I am honored to be able to do what I do, every day.”